Biggest Need for New Jersey’s STEM Future: Keeping Our Talent Here
March 1, 2023
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Anthony S. Cicatiello, President of the R&D Council of New Jersey …
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Anthony S. Cicatiello, President of the R&D Council of New Jersey …
About 1 in 11 Americans, and 350 million people worldwide, suffer from a rare disease, defined as a disease affecting less than 200,000 people in the United States. …
The Star-Ledger’s recent editorial, “Drug prices are obscene, and (Gov. Phil) Murphy is blocking the smart solution,” left out key facts regarding the role of drug manufacturers in determining what patients pay for name-brand medicines. …
Trenton, July 29, 2022 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning
Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation.
Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation in a reconciliation package.
Steve Issenman
Senior V.P.
732-729-9621
issenman@hinj.org